IL6 and arthropathy: The clinical efficacy of anti-TNF-α drugs in patients with psoriasis and/or joint disease was associated with (i) reduction of IL-6 and IL-22 in sera; (ii) increments of regulatory T cells; (iii) reduction of cutaneous homing receptor expressing T cells.